A busy session for healthcare news saw Creo Medical lead the way with upgraded full-year guidance after a strong first quarter, while Futura Medical overhauled its US commercial strategy for Eroxon and AstraZeneca's Datroway secured a key European approval recommendation for triple-negative breast cancer. Smaller names Verici Dx and genedrive also posted meaningful commercial progress.
Creo Medical lifts FY26 revenue growth guidance after Q1 beat
Creo Medical Group (AIM:CREO) raised its full-year revenue growth forecast to 50-60% after first-quarter sales came in at the top of management's expectations. The surgical device maker had previously guided to a lower range, and the upgrade reflects accelerating commercial momentum across its advanced energy and electrosurgical portfolio. Shares responded sharply, rising 8.3% to 14.625p.
Verici Dx posts first full-year Tutivia revenues as test adoption triples
Verici Dx (AIM:VRCI) reported its first full year of recognised revenues from its Tutivia kidney rejection test, recording $2.9 million for 2025 as commercial adoption gathered pace. The transplant diagnostics company added that Q1 volumes were already running 32% ahead of the prior quarter, suggesting the trajectory is continuing into the current year. Shares were quoted at 0.375p.
Futura Medical replaces Haleon with MPG for US Eroxon distribution
Futura Medical (AIM:FUM) terminated its US partnership with Haleon for the Eroxon erectile dysfunction gel, receiving a $1.9 million early termination fee in the process. The company simultaneously signed a new distribution agreement with Market Performance Group, with the transition of commercial control scheduled for 1 September. The move represents a deliberate shift towards a more focused US distribution partner, and the shares edged up 3.2% to 0.518p on the news.
Genedrive partners Thermo Fisher to develop NHS pharmacogenetic test
genedrive (AIM:GDR) announced a development partnership with Thermo Fisher Scientific to create a laboratory-based pharmacogenetic test for deployment on Thermo Fisher's QuantStudio 5 Dx platform. The test is targeted at the UK NHS genomic laboratory market, positioning genedrive within the growing clinical pharmacogenomics segment. Shares added 1.9% to 1.325p.
AstraZeneca's Datroway wins EU committee backing for breast cancer first-line use
AstraZeneca (LSE:AZN) received a positive recommendation from Europe's medicines committee for Datroway, its antibody drug conjugate developed with Daiichi Sankyo, in the first-line treatment of triple-negative breast cancer patients ineligible for immunotherapy. The committee cited a five-month overall survival gain over chemotherapy as the basis for its backing, a meaningful clinical benchmark in a historically difficult-to-treat indication. AstraZeneca shares were broadly flat at 14,320p, up just 0.01%, as the market had largely anticipated the regulatory outcome.
